GlyHealth-COVID is being developed to identify immunofrail individuals likely to suffer serious inflammatory episodes if they were to be infected with SARS-Cov-2 virus.
The first phase of this program was being funded as part of the UK Research and Innovation (UKRI) initiative for research addressing COVID-19 with blood samples from patients across the UK, Europe and the US. See more details here. Our preliminary results indicate that there are blood glycomics patterns of individuals that seem to correlate with health outcomes after SARS-Cov-2 infection.
There are no reviews yet.